Endocrine-Related Cancer

Papers
(The TQCC of Endocrine-Related Cancer is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)
ArticleCitations
The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms73
Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms55
The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading49
Therapy considerations in neuroendocrine prostate cancer: what next?44
The tumor microenvironment and immune responses in prostate cancer patients42
The role of vitamin D in breast cancer risk and progression42
Duality of glucocorticoid action in cancer: tumor-suppressor or oncogene?35
Obese adipose tissue extracellular vesicles raise breast cancer cell malignancy34
HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomas34
Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns34
The role of delta-like non-canonical Notch ligand 1 (DLK1) in cancer33
Thyroid cancer in the age of COVID-1932
Redifferentiation-facilitated radioiodine therapy in thyroid cancer31
The natural history and treatment of non-functioning pituitary adenomas (non-functioning PitNETs)28
The complex regulation of NIS expression and activity in thyroid and extrathyroidal tissues27
Molecular alterations in Hürthle cell nodules and preoperative cancer risk27
New therapeutic opportunities for women with low-grade serous ovarian cancer26
The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches25
50th anniversary of the first clinical trial with ICI 46,474 (tamoxifen): then what happened?24
Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review24
The sodium iodide symporter (NIS): novel applications for radionuclide imaging and treatment24
Epigenetic and metabolic reprogramming of SDH-deficient paragangliomas23
Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer23
Novel insights in cell cycle dysregulation during prostate cancer progression22
Androgen receptor mutations for precision medicine in prostate cancer22
Genomic classification of benign adrenocortical lesions21
Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine21
Neuroendocrine neoplasms of lung, pancreas and gut: a morphology-based comparison21
Metabolic and hormonal remodeling of colorectal cancer cell signaling by diabetes20
Role of circadian rhythm disorders on EMT and tumour–immune interactions in endocrine-related cancers20
Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer20
SREBP1 promotes invasive phenotypes by upregulating CYR61/CTGF via the Hippo-YAP pathway20
Targeting EML4-ALK gene fusion variant 3 in thyroid cancer18
Genome-wide crosstalk between steroid receptors in breast and prostate cancers18
Tailoring the approach to radioactive iodine treatment in thyroid cancer18
Risk factors for intraoperative complications in pheochromocytomas18
Advanced RAI-refractory thyroid cancer: an update on treatment perspectives18
The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal18
Improved pasireotide response in USP8 mutant corticotroph tumours in vitro17
Phosphodiesterase 2A and 3B variants are associated with primary aldosteronism17
Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC17
Follow-up of patients with thyroid cancer and antithyroglobulin antibodies: a review for clinicians17
Treatment outcomes of advanced digestive well-differentiated grade 3 NETs17
Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET17
Translating the immune microenvironment of thyroid cancer into clinical practice16
B7 immune-checkpoints as targets for the treatment of neuroendocrine tumors16
The role of membrane mucin MUC4 in breast cancer metastasis16
Metastatic medullary thyroid carcinoma: a new way forward16
Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures16
USP8 inhibitor RA-9 reduces ACTH release and cell growth in tumor corticotrophs15
Targeted genomic analysis of 364 adrenocortical carcinomas15
Exercise intensity and markers of inflammation during and after (neo-) adjuvant cancer treatment15
KLF5 and NFYA factors as novel regulators of prostate cancer cell metabolism15
Molecular connections between circadian rhythm and genome maintenance pathways14
Critical appraisal of MGMT in digestive NET treated with alkylating agents14
Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview14
Adiponectin receptor activation inhibits prostate cancer xenograft growth14
Inferior outcome of neuroendocrine tumor patients negative on somatostatin receptor imaging14
Diagnosis and management of parathyroid carcinoma: a state-of-the-art review14
Gene expression profile in metastatic and non-metastatic parathyroid carcinoma13
Serine synthesis influences tamoxifen response in ER+ human breast carcinoma13
The thyroid risk score (TRS) for nodules with indeterminate cytology13
Changing biological behaviour of NETs during the evolution of the disease: progress on progression13
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms13
Percutaneous ablation of low-risk papillary thyroid cancer12
Update on the genetics of paragangliomas12
TREM1 fosters an immunosuppressive tumor microenvironment in papillary thyroid cancer12
100 years of the Warburg effect: a historical perspective12
Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers12
BRAFV600E restructures cellular lactylation to promote anaplastic thyroid cancer proliferation11
Leptin-elicited PBX3 confers letrozole resistance in breast cancer11
The GIP/GIPR axis in medullary thyroid cancer: clinical and molecular findings11
Outcome of patients with intrathyroidal thymic carcinoma: a pooled analysis11
Loss of sdhb in zebrafish larvae recapitulates human paraganglioma characteristics11
Developmental role of PHD2 in the pathogenesis of pseudohypoxic pheochromocytoma11
Advances in paraganglioma–pheochromocytoma cell lines and xenografts11
Stress hormone norepinephrine incites resistance of oral cancer cells to chemotherapy11
Na+/I− symporter expression, function, and regulation in non-thyroidal tissues and impact on thyroid cancer therapy11
SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma11
Thyroid status regulates the tumor microenvironment delineating breast cancer fate10
Dsg2-mediated c-Met activation in anaplastic thyroid cancer motility and invasion10
SYT7 plays a role in promoting thyroid cancer by mediating HMGB3 ubiquitination10
Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance)10
Leptin antagonism inhibits prostate cancer xenograft growth and progression10
Long-term survival of metastatic small intestine neuroendocrine tumors: a meta-analysis10
Aggressive versus indolent insulinomas: new clinicopathological insights10
Remodelling of colorectal cancer cell signaling by microbiota and immunity in diabetes10
Exploring stem cell biology in pituitary tumors and derived organoids10
Adrenal tumors provide insight into the role of cortisol in NK cell activity10
New drug delivery strategies targeting the GnRH receptor in breast and other cancers10
Pan-genomic characterization of high-risk pediatric papillary thyroid carcinoma10
Inhibition of GATA2 in prostate cancer by a clinically available small molecule10
Dysregulation of splicing variants and spliceosome components in breast cancer10
Microglial NLRP3 inflammasome activation-mediated inflammation promotes prolactinoma development9
Integrin αvβ3-dependent thyroid hormone effects on tumour proliferation and vascularisation9
PRKACB variants in skeletal disease or adrenocortical hyperplasia: effects on protein kinase A9
A novel liquid biopsy (NETest) identifies paragangliomas and pheochromocytomas with high accuracy9
Metabolomics in paraganglioma: applications and perspectives from genetics to therapy9
Effect of TSH levels during active surveillance of PTMC according to age9
Targeting androgen receptor signaling: a historical perspective9
Development of improved SRC-3 inhibitors as breast cancer therapeutic agents9
Immunotherapy-induced isolated ACTH deficiency in cancer therapy9
0.077605009078979